Secukinumab
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL) -17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis[1][2].
Product Specifications
CAS Number
[1229022-83-6]
Product Name Alternative
AIN457
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/secukinumab.html
Purity
99.20
Solubility
H2O
Smiles
[Secukinumab]
Molecular Weight
(147.82 kDa)
References & Citations
[1]Shirley M, et al. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2016;76 (11) :1135-1145.|[2]Reich K, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182 (2) :304-315.|[3]Elain G, et al. The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia. 2014;62 (5) :725-735.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-17
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
